Education
About Us
Working with TipRanks
Follow Us
Generation Bio Co. (GBIO)
NASDAQ:GBIO
GBIO Stock Chart & Stats
$5.11
-$0.05(-4.79%)
At close: 4:00 PM EST
$5.11
-$0.05(-4.79%)
Day’s Range― - ―
52-Week Range$3.00 - $25.70
Previous CloseN/A
Volume226.22K
Average Volume (3M)52.92K
Market Cap
$35.36M
Enterprise Value-$34.58M
Total Cash (Recent Filing)$89.62M
Total Debt (Recent Filing)$26.10M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Mar 12, 2026EPS Estimate
-2.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding6,735,544
10 Day Avg. Volume46,579
30 Day Avg. Volume52,917
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)0.82
Price to Sales (P/S)3.55
P/FCF Ratio-0.78
Enterprise Value/Market Cap-0.98
Enterprise Value/Revenue-2.26
Enterprise Value/Gross Profit-2.53
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$11.00Price Target Upside115.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash PositionAnalysts see value in the highly differentiated LNP platform and note the significant cash balance expected to last into the foreseeable future.
SiRNA Delivery MilestoneNew in vivo NHP results represent a major milestone for Generation Bio's ctLNP platform.
Technology AdvancementRecent preclinical data showed Generation's ctLNPs successfully achieved selective delivery of siRNA to T-cells in NHPs.
Bears Say
Pursuing Strategic AlternativesGeneration Bio has been pursuing strategic alternatives including but not limited to potential M&A, partnerships, or asset sales.
Strategic UncertaintyThere is increased uncertainty around the company's path forward and potential ability to achieve strategic goals.
Workforce ReductionThe company's second announcement was a 90% workforce reduction to preserve cash as it explores strategic alternatives.
Generation Bio News
GBIO FAQ
What was Generation Bio Co.’s price range in the past 12 months?
Generation Bio Co. lowest stock price was $3.00 and its highest was $25.70 in the past 12 months.
What is Generation Bio Co.’s market cap?
Generation Bio Co.’s market cap is $35.36M.
When is Generation Bio Co.’s upcoming earnings report date?
Generation Bio Co.’s upcoming earnings report date is Mar 12, 2026 which is in 124 days.
How were Generation Bio Co.’s earnings last quarter?
Generation Bio Co. released its earnings results on Nov 05, 2025. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$3.15 by $2.33.
Is Generation Bio Co. overvalued?
According to Wall Street analysts Generation Bio Co.’s price is currently Undervalued.
Does Generation Bio Co. pay dividends?
Generation Bio Co. does not currently pay dividends.
What is Generation Bio Co.’s EPS estimate?
Generation Bio Co.’s EPS estimate is -2.6.
How many shares outstanding does Generation Bio Co. have?
Generation Bio Co. has 6,735,544 shares outstanding.
What happened to Generation Bio Co.’s price movement after its last earnings report?
Generation Bio Co. reported an EPS of -$0.82 in its last earnings report, beating expectations of -$3.15. Following the earnings report the stock price went down -3.276%.
Which hedge fund is a major shareholder of Generation Bio Co.?
Currently, no hedge funds are holding shares in GBIO
Generation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (115.26% Upside)
$11.00 (115.26% Upside)
Hedge Fund Trend
Decreased
By 60.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.24%
12-Months-Change
Fundamentals
Return on Equity
-80.81%
Trailing 12-Months
Asset Growth
-32.36%
Trailing 12-Months
Company Description
Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
GBIO Stock 12 Month Forecast
Average Price Target
$11.00
▲(115.26% Upside)
Technical Analysis
FibroGen
―
Grace Therapeutics
―
LAVA Therapeutics
―
OnKure Therapeutics
―
Xilio Therapeutics
―
Ownership Overview
17.72% Insiders
21.60% Mutual Funds
21.87% Other Institutional Investors
34.63% Public Companies and
Individual Investors